Clinical trial Recruiting at 1 site Phase 3 Interventional

RECOMMEND platform testing interventions for adults receiving ECMO

Official title: Generating New Evidence to Reduce Major Complications to Improve the Safety and Efficacy of ECMO in Severe Cardiac and Respiratory Failure (RECOMMEND)

Run by Australian and New Zealand Intensive Care Research Centre · NCT06526533 · Data updated 2026-11-12

This platform tests whether different treatments, such as liberal versus restrictive red blood cell transfusion strategies, help adults on ECMO survive and need less organ support and hospital resources by day 28.

Quick facts

PhasePhase 3
Study typeInterventional
SexAll
Enrollment600 (estimated)
SponsorAustralian and New Zealand Intensive Care Research Centre
Academic / other
Locations3 sites (Camperdown, New South Wales and 2 other locations)
StatusRecruiting
StartedMarch 23, 2026
Main results expectedJune 2028
Study endsJune 2029
Registry record updatedMay 13, 2026
Trial IDNCT06526533 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (≥18 years) receiving ECMO at a participating Australian ICU who are enrolled in the EXCEL registry and meet the domain-specific inclusion criteria are eligible.

Probably not a fit

Patients with imminent, unavoidable death, those with contraindications to a domain intervention (for example refusal of blood transfusion), or those expected to cease ECMO within 24 hours are unlikely to benefit from enrollment.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

RECOMMEND is an investigator-initiated, multicentre, open-label randomized adaptive platform conducted in Australian ICUs using Bayesian logic to compare multiple interventions for adults receiving ECMO. Participants are enrolled via the national EXCEL registry and allocated within domain structures to receive interventions either simultaneously or sequentially, with primary outcomes of survival, organ support and resource use to day 28. One core domain compares liberal versus restrictive red blood cell transfusion thresholds, and additional domains can be added or stopped based on adaptive analyses. The design aims to efficiently identify effective, safe, and cost-effective strategies for this high-risk, resource-intensive population.

Why it matters

Potential benefit: If successful, the platform could identify treatments that increase survival, shorten time on organ support, and reduce ICU costs for people receiving ECMO.

How similar studies have gone: Adaptive platform trials and transfusion-threshold trials in critical care have produced useful results, but an adaptive platform focused specifically on ECMO patients is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
PLATFORM INCLUSION CRITERIA:

* Patients receiving ECMO
* Patients enrolled in the EXCEL Registry - NCT03793257

PLATFORM EXCLUSION CRITERIA:

* Treating clinician regards death as imminent and inevitable
* Treating clinician determines it is not in the patient's best interests

RBC TRANSFUSION DOMAIN INCLUSION CRITERIA:

• Aged 18 years or older

RBC TRANSFUSION DOMAIN EXCLUSION CRITERIA:

* Contraindication to RBC transfusion (including known patient preference)
* Limitations of care put in place either through patient wishes or the treating medical teams.
* Participant has already received ECMO \>12 hours. The start of ECMO is defined as the time of initiation of extracorporeal blood flow unless ECMO was initiated during a surgical intervention in which case the start of ECMO is defined as the arrival time into the initial ICU (post-surgery)
* The treating physician anticipates that ECMO treatment will cease before the end of tomorrow
* The treating physician deems the study is not in the patient's best interest
* The treating physician has concern regarding patient ability to tolerate restrictive or liberal transfusion trigger thresholds
* Actively listed for a solid organ transplant and has not yet received one
* Suspected or confirmed to be pregnant
* Previous ECMO treatment during the same hospital admission

Where it's running

  • St. Vincent's Hospital Sydney
    Sydney, New South Wales, Australia
    Recruiting
  • Royal Prince Alfred Hospital
    Camperdown, New South Wales, Australia
    Not yet recruiting
  • The Alfred Hospital
    Melbourne, Victoria, Australia
    Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.